{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:10:02Z","timestamp":1741968602638,"version":"3.38.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"2","funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1080\/03007995.2025.2465649","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T11:52:32Z","timestamp":1739447552000},"page":"329-338","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Real-world prevalence of potential drug\u2013drug interactions associated with oral advanced therapies indicated for ulcerative colitis"],"prefix":"10.1080","volume":"41","author":[{"given":"Maryia","family":"Zhdanava","sequence":"first","affiliation":[{"name":"Analysis Group, Inc.","place":["Montr\u00e9al, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabree","family":"Burbage","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todor I.","family":"Totev","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian","family":"Diaz","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Montr\u00e9al, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget","family":"Godwin","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Montr\u00e9al, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Montr\u00e9al, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.07.003"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0205-x"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000152"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.03.002"},{"issue":"4","key":"e_1_3_7_6_1","first-page":"3","article-title":"The guide to guidelines in ulcerative colitis: interpretation and appropriate use in clinical practice","volume":"17","author":"Sandborn WJ","year":"2021","unstructured":"Sandborn WJ, Feagan BG, Hanauer SB, et\u00a0al. The guide to guidelines in ulcerative colitis: interpretation and appropriate use in clinical practice. Gastroenterol Hepatol (NY). 2021;17(4 Suppl 4):3\u201313.","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01169-y"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2020.1785868"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211041907"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000435442.07237.a4"},{"key":"e_1_3_7_13_1","volume-title":"Highlights of prescribing information","author":"Pfizer Inc","year":"2018","unstructured":"Pfizer Inc. Xeljanz\/Xeljanz XR (tofacitinib citrate). In Highlights of prescribing information. New York, NY: U.S. Food and Drug Administration; 2018."},{"key":"e_1_3_7_14_1","volume-title":"Highlights of prescribing information","author":"Abbvie Inc.","year":"2022","unstructured":"Abbvie Inc. RINVOQ (upadacitinib). In Highlights of prescribing information. North Chicago, IL: U.S. Food and Drug Administration; 2022."},{"key":"e_1_3_7_15_1","volume-title":"Highlights of prescribing information","author":"Celgene Corporation","year":"2022","unstructured":"Celgene Corporation. ZEPOSIA (ozanimod). In Highlights of prescribing information. Summit, NJ: U.S. Food and Drug Administration; 2022."},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1758047"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100070"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwaa001"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.8.907"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1021353"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000233295"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.3163\/1536-5050.104.4.007"},{"issue":"2","key":"e_1_3_7_23_1","first-page":"130","article-title":"Quality and usability of common drug information databases","volume":"63","author":"Mountford CM","year":"2010","unstructured":"Mountford CM, Lee T, de Lemos J, et\u00a0al. Quality and usability of common drug information databases. Can J Hosp Pharm. 2010;63(2):130\u2013137.","journal-title":"Can J Hosp Pharm"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.07.046"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab030"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i24.5468"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac141"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2018.06.002"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.825041"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420952423"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1366"},{"key":"e_1_3_7_33_1","unstructured":"European Public Assessment Report \u2013 summary of risk management plan for ZEPOSIA (ozanimod); Version 7.1. European Medicines Agency. 2023."},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000855"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2025.2465649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:55:20Z","timestamp":1741967720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2025.2465649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1080\/03007995.2025.2465649"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2025.2465649","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"type":"print","value":"0300-7995"},{"type":"electronic","value":"1473-4877"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}